Clinical trial Recruiting at 1 site Interventional Ages 21 to 50

Left DLPFC rTMS vs iTBS for emotional dysregulation, impulsivity, and NSSI in Borderline Personality Disorder

Official title: Effect of Repetitive Transcranial Magnetic Stimulation Versus Theta Burst Stimulation on Impulsivity, Emotional Dysregulation, and Non-Suicidal Self-Injury in a Sample of Patients With Borderline Personality Disorder: A Randomized Controlled Trial

Run by Ain Shams University · NCT07919587 · Data updated 2026-11-12

This trial tests whether high-frequency rTMS or intermittent theta-burst stimulation over the left DLPFC can help reduce emotional instability, impulsivity, and non-suicidal self-injury in adults with Borderline Personality Disorder.

More Borderline Personality Disorder (BPD) trials

Quick facts

Study typeInterventional
Ages21 Years to 50 Years
SexAll
Enrollment45 (estimated)
SponsorAin Shams University
Academic / other
Locations1 site (Cairo, Cairo Governorate)
StatusRecruiting
StartedDecember 1, 2025
Main results expectedJune 2027
Study endsAugust 2027
Registry record updatedNovember 5, 2026
Trial IDNCT07919587 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 21-50 with a diagnosis of Borderline Personality Disorder who are able to participate in neuromodulation sessions and continue standard therapy.

Probably not a fit

Individuals with contraindications to TMS, or those whose symptoms do not respond to brain stimulation in this study, may not see benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind study compares three groups: high-frequency rTMS, intermittent theta-burst stimulation (iTBS), and sham stimulation, all targeting the left dorsolateral prefrontal cortex. Participants with Borderline Personality Disorder receive brain stimulation while continuing standard therapy, to see which approach best improves emotional regulation, impulsivity, and self-injury behaviors. Each session lasts about 21 minutes, with stimulation parameters defined (rTMS: 5 Hz, 1200 pulses, 80-110% RMT; iTBS: 50 Hz bursts, 600 pulses, 80-120% RMT). Outcomes will be compared to sham after the treatment course. The study is conducted at Ain Shams University Hospitals in Cairo, focusing on adults aged 21-50.

Why it matters

Potential benefit: If successful, patients could experience better emotional control, fewer impulsive actions, and reduced self-injury behaviors.

How similar studies have gone: Previous neuromodulation studies in related conditions suggest potential benefits, but direct evidence in Borderline Personality Disorder remains emerging.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1\. Age range: 21-50 years old. 2. Gender: males and females 3. Borderline personality disorder diagnosis

Exclusion Criteria:

\- 1. Presence of other uncontrolled mental illness that precludes the ability to provide informed consent (e.g.; acute psychosis, bipolar disorder currently in manic episode, major depressive disorder with recent suicidal attempt).

2\. Patients with contraindications to TMS as cardiac patients with pacemakers, metallic implants as cochlear implants, aneurysm clips, stents, and deep brain stimulation electrodes.

Where it's running

  • Ainshams University Hospitals
    Cairo, Cairo Governorate, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.